Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Diatrizoate Sodium is an X-ray contrast agent. By obstructing X-rays, the diatrizoate sodium drug enables the differentiation between iodine-containing and iodine-free body structures. Radiography, angiography, and urography all use this as a diagnostic tool.
ln Vitro |
For two to twenty-four hours, HK-2 cells were treated to either a vehicle or 0–30 mg I/mL sodium diatrizoate (sodium diatrizoate salt). According to the MTT and trypan blue exclusion experiments, cell viability and mitochondrial content drop after two and twenty-four hours, respectively [2].
|
---|---|
ln Vivo |
Sodium diatrizoate is an iodinated radiographic contrast agent. After insufflation of sodium diatrizoate nanoparticle aggregates, histological analysis of rat lung tissue revealed no acute toxicity or inflammation. Sodium diatrizoate nanoparticle agglomerates present a promising alternative for safe and efficient lung visualization [1].
|
References |
[1]. El-Gendy N, et al. Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. Int J Pharm. 2010 May 31;391(1-2):305-12.
[2]. Dakota B Ward, et al. Radiocontrast Agent Diatrizoic Acid Induces Mitophagy and Oxidative Stress via Calcium Dysregulation. Int J Mol Sci. 2019 Aug 21;20(17):4074 |
Molecular Formula |
C11H8I3N2NAO4
|
---|---|
Molecular Weight |
635.89
|
Exact Mass |
635.7516
|
Elemental Analysis |
C, 20.78; H, 1.27; I, 59.87; N, 4.41; Na, 3.62; O, 10.06
|
CAS # |
737-31-5
|
Related CAS # |
Diatrizoic acid;117-96-4
|
Appearance |
Solid powder
|
SMILES |
CC(=O)NC1=C(C(=C(C(=C1I)C(=O)[O-])I)NC(=O)C)I.[Na+]
|
InChi Key |
ZEYOIOAKZLALAP-UHFFFAOYSA-M
|
InChi Code |
InChI=1S/C11H9I3N2O4.Na/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18;/h1-2H3,(H,15,17)(H,16,18)(H,19,20);/q;+1/p-1
|
Chemical Name |
sodium;3,5-diacetamido-2,4,6-triiodobenzoate
|
Synonyms |
Diatrizoate sodium; Hypaque; MD-50; MD50; MD 50; Urovist Sodium; Triombrin
|
HS Tariff Code |
2934.99.03.00
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~100 mg/mL (~157.3 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 33.33 mg/mL (52.41 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.5726 mL | 7.8630 mL | 15.7260 mL | |
5 mM | 0.3145 mL | 1.5726 mL | 3.1452 mL | |
10 mM | 0.1573 mL | 0.7863 mL | 1.5726 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03573921 | Recruiting | Drug: Gastrografin Other: Saline solution (control treatment) |
Small Bowel Obstruction | Lawson Health Research Institute | September 1, 2019 | Phase 2 Phase 3 |
NCT01440712 | Completed | Drug: Gastrografin Drug: physiological serum |
Postoperative Ileus | Hospital Universitari de Bellvitge | December 2011 | Phase 4 |
NCT00738855 | Completed | Other: Nothing per os Other: Oral Gastrografin |
Small Bowel Obstruction | Mansoura University | February 2006 | Not Applicable |
NCT00389116 | Completed | Drug: gastrograffin Drug: water |
Small Bowel Obstruction | University Hospital, Rouen | November 2006 | Phase 4 |
NCT01515696 | Completed | Drug: Sterile water Drug: Gastrografin |
Meconium Ileus Very Low Birth Weight Infant |
Nadja Haiden,MD | October 2007 | Phase 4 |